Active, Not Recruiting
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
NCT04034927
- Conditions
- Adnexal Diseases, Fallopian Tube Diseases, Fallopian Tube Endometrioid Tumor, +23 more
- Locations
-
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- Hartford Hospital Hartford, Connecticut, United States
- Augusta University Medical Center Augusta, Georgia, United States